Patents by Inventor Ralf Hosse

Ralf Hosse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-FAP antibodies and methods of use
    Patent number: 12286486
    Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: April 29, 2025
    Assignee: Roche Glycart AG
    Inventors: Marina Bacac, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Bispecific antibodies specific for OX40
    Patent number: 12240911
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) at least one moiety capable of specific binding to a costimulatory TNF receptor family member, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: March 4, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Viktor Levitski, Pablo Umana
  • Antibodies binding to CD3 and CD19
    Patent number: 12215155
    Abstract: The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: August 8, 2023
    Date of Patent: February 4, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Anne Freimoser-Grundschober, Maria Valeria Gonzalez Nicolini, Ralf Hosse, Alexander Knaupp, Ekkehard Moessner, Wolfgang Richter, Halina Trochanowska, Pablo Umaña, Christian Klein, Inja Waldhauer
  • AGONISTIC LTBR ANTIBODIES AND BISPECIFIC ANTIBODIES COMPRISING THEM
    Publication number: 20250034269
    Abstract: The invention relates to novel antibodies that bind to lymphotoxin beta receptor (LTBR) and to bispecific antigen binding molecules comprising these novel LTBR antibodies and an antigen binding domain that binds a tumor associated antigen, in particular to Fibroblast Activation Protein (FAP), to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: June 18, 2024
    Publication date: January 30, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Roberta Bianchi, Felix Bormann, Michelle Victoria Brydon, Stefan Dengl, Harald Duerr, Guy Georges, Lydia Jasmin Hanisch, Monika Heidrich, Ralf Hosse, Leo Frederik Kunz, Stephane Leclair, Desirée Leisibach, Fanny Mende, Olaf Mundigl, Miroslav Nikolov, Pablo Umaña, Cornelia Wagner
  • T cell activating bispecific antigen binding molecules
    Patent number: 12139553
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target 511cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: January 20, 2022
    Date of Patent: November 12, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Peter Bruenker, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
  • T cell activating bispecific antigen binding molecules
    Patent number: 12103982
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: October 1, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Ekkehard Moessner, Ralf Hosse, Peter Bruenker, Pablo Umana, Christiane Neumann
  • Bispecific antibodies against CD3EPSILON and ROR1
    Patent number: 11952421
    Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: April 9, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
  • Antibodies binding to NKG2D
    Patent number: 11827711
    Abstract: The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: November 28, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Ralf Hosse, Inja Waldhauer, Christian Klein, Pablo Umana
  • ANTI-CEA ANTIBODIES
    Publication number: 20230365711
    Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
    Type: Application
    Filed: March 9, 2023
    Publication date: November 16, 2023
    Applicant: Roche Glycart AG
    Inventors: Thomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
  • Bispecific HER2 antibodies and methods of use
    Patent number: 11787873
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: October 17, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • Antibodies binding to CD3 and CD19
    Patent number: 11780920
    Abstract: The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: October 10, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Anne Freimoser-Grundschober, Maria Valeria Gonzalez Nicolini, Ralf Hosse, Alexander Knaupp, Ekkehard Moessner, Wolfgang Richter, Halina Trochanowska, Pablo Umaña, Christian Klein, Inja Waldhauer
  • Bispecific antibody molecules binding to CD3 and TYRP-1
    Patent number: 11672858
    Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 13, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Anne Freimoser-Grundschober, Thomas Hofer, Ralf Hosse, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umaña, Inja Waldhauer, Wolfgang Richter, Alexander Knaupp, Halina Trochanowska
  • Tumor-targeted agonistic CD28 antigen binding molecules
    Patent number: 11608376
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: March 21, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Jenny Thom, Stephan Gasser, Jean-Baptiste Vallier, Tanja Fauti
  • Bispecific antibody molecules binding to CD3 and EGFRvIII
    Patent number: 11591397
    Abstract: The present invention generally relates to antibodies that bind to CD3, including multi specific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: February 28, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Anne Freimoser-Grundschober, Thomas Hofer, Ralf Hosse, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umaña, Inja Waldhauer, Wolfgang Richter, Alexander Knaupp, Halina Trochanowska
  • FUSION OF AN ANTIBODY BINDING CEA AND 4-1BBL
    Publication number: 20220267464
    Abstract: The invention relates to new humanized CEA antibodies and to CEA targeting 4-1BBL trimer-containing antigen binding molecules comprising these CEA antibodies as well as their use in the treatment of cancer.
    Type: Application
    Filed: December 17, 2021
    Publication date: August 25, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia Ferrara Koller, Thomas Hofer, Christian Klein, Ekkehard Moessner, Christina Claus, Ralf Hosse, Bianca Scherer, Pablo Umana
  • Interleukin-2 fusion proteins and uses thereof
    Patent number: 11365232
    Abstract: The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: June 21, 2022
    Assignee: Roche Glycart AG
    Inventors: Ralf Hosse, Christian Klein, Ekkehard Moessner, Laurence Bernard Peterson, Pablo Umana, Linda Wicker
  • Anti-FAP antibodies and methods of use
    Patent number: 11332545
    Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: May 17, 2022
    Assignee: ROCHE GLYCART AG
    Inventors: Marina Bacac, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Antibodies binding to CD3 and CD19
    Publication number: 20220010014
    Abstract: The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: June 17, 2021
    Publication date: January 13, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Anne Freimoser-Grundschober, Maria Valeria Gonzalez Nicolini, Ralf Hosse, Alexander Knaupp, Ekkehard Moessner, Wolfgang Richter, Halina Trochanowska, Pablo Umaña, Christian Klein, Inja Waldhauer
  • ANTI-CEA ANTIBODIES
    Publication number: 20220002441
    Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
    Type: Application
    Filed: September 24, 2021
    Publication date: January 6, 2022
    Inventors: Thomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
  • Antibodies specific for DR5 and methods of use
    Patent number: 11214622
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: January 4, 2022
    Assignee: ROCHE GLYCART AG
    Inventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser